跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2020/11/028831
CTRI/2020/11/028831尚未招募未知

A Multicenter, Double-Blind, Randomized, Three arm, Active and Placebo Controlled, Parallel Study to Evaluate the Bioequivalence (with clinical endpoint) of Adapalene Gel, 0.1% of THINQ Pharma-CRO Private Limited, 111 North bridge road, #16-04, Peninsula plaza, Singapore-179098 to DIFFERIN® (Adapalene Gel, 0.1%) of Galderma Laboratories LP Fort Worth, Texas 76177 USA in subjects with Acne Vulgaris. -

THINQ PharmaCRO Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
未知
状态
尚未招募
发起方
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ba/be

入排标准

入选标准

  • •1)Male or non-pregnant, non-lactating female aged 12 to 40 years with a clinical diagnosis of acne vulgaris with facial involvement.
  • •2)Written informed consent had to be obtained and for Subjects aged 12 to 17 years, had to sign an assent for the study and a parent or a legal guardian had to sign the informed consent.
  • •3)On the face, greater than or equal to 25 non-inflammatory lesions (i.e., open and closed comedones) and greater than or equal to 20 inflammatory lesions (i.e., papules and pustules) and less than or equal to 2 nodulocystic lesions (i.e., nodules and cysts).
  • •4)Investigatorâ??s Global Assessment (IGA) of acne severity grade 2, 3 or 4 (refer the table below).
  • •ScoreDescription
  • •0 Clear skin with no inflammatory or non-inflammatory lesions.
  • •1 Almost clear; rare non-inflammatory lesions with no more than one small inflammatory lesion.
  • •2 Mild severity; greater than Grade 1;Some non-inflammatory lesions with no more than a few inflammatory lesions (papules/pustules only,
  • •no nodular lesions)
  • •3 Moderate Severity; greater than Grade 2; up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion.
  • •4 Severe; greater than Grade 3; up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than a few nodular lesions
  • •5.Willing to refrain from use of all other topical acne medications or antibiotics during the 12 weeks treatment period.
  • •6.Male subjects and female of childbearing potential, willing to use an acceptable form of birth control during the study period.
  • •7.Have used the same brand of make-up for a minimum period of 2 weeks prior to randomization, for subjects who use make-up, and agree to not change make-up brands or types during the study.

排除标准

  • •1.Females who are breast feeding, pregnant or planning to become pregnant.
  • •2.Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).
  • •3.Subjects who have acne conglobata, acne fulminans and secondary acne (e.g., chloracne and drug induced acne).
  • •4.Excessive facial hair (e.g. beards, sideburns, moustaches, etc.), tattoos that would interfere with diagnosis or assessment of acne vulgaris. Well-trimmed moustaches are allowed. Subjects who have performed wax epilation of the face within 14 days prior to baseline.
  • •5.History of hypersensitivity or allergy to adapalene, retinoids and/or any of the study medication ingredients.
  • •6.Subjects who have a severe or intense irritation on the Face.
  • •7.Use within 6 months prior to baseline (Randomization) or during the study of oral retinoids (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
  • •8.Use for less than 3 months prior to baseline (Randomization) of estrogens or oral contraceptives; use of such therapy is allowed, if it will remain constant throughout the study.
  • •9.Use on the face within 1 month prior to baseline (Randomization) or during the study of: a) cryo destruction or chemo destruction, b) dermabrasion, c) photodynamic therapy, d) acne surgery, e) intralesional steroids, or f) x-ray therapy, or g) chemical or laser peel.
  • •10.Use within 1 month prior to baseline (Randomization) of: a) androgen receptor blockers for acne (such as spironolactone or flutamide), b) systemic steroids (including intranasal and inhaled corticosteroids),c)systemic antibiotics, d) systemic treatment for acne vulgaris (other than oral retinoids, which require a 6-month washout), or e) systemic anti-inflammatory agents.
  • •11)Use within 2 weeks prior to baseline or during the study of a) topical steroids, b) topical retinoids,c)topical acne treatments including over-the-counter preparations, d) topical anti-inflammatory agents, or e) topical antibiotics.
  • •l2)Use of astringents and toners for less than 2 weeks prior to the start of the study.
  • •13)Use of abradants, facials, peels containing glycolic or other acids, masks; washes or soaps containing benzoyl peroxide, salicylic acid, or sulfacetamide sodium; non-mild facial cleansers; moisturizers that contained retinol, salicylic acid or alpha or beta hydroxy acids within the previous 2 weeks.
  • •14)Concomitant use/planned to use of mega-doses of certain vitamins (such as vitamin D [ > 2000 IU/day], vitamin B6 [ > 2 mg/day] and vitamin B12 [ > 1 mg/day]), haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.
  • •15)Anti-pruritic, including antihistamines, within 24 hours of baseline visits.
  • •16)Use of tanning booths or tanning lamps within 1 week prior to baseline and an unwillingness to refrain from use during the study.
  • •17)A significant medical history of or are currently immunocompromised or receiving immunomodulators/biologics since last 3 months.
  • •18)Have any systemic or dermatologic

研究者

发起方
THINQ PharmaCRO Private Limited

相似试验

已完成
不适用
Comparison of Tretinoin Cream 0.10% from Encube Ethicals Pvt. India Ltd with RETIN-A (Tretinoin) Cream, 0.10% (Bausch Health US, LLC Bridgewater, NJ 08807 USA) and placebo in the treatment of acne vulgaris.
CTRI/2022/11/047270Encube Ethicals Private Limited610
已完成
不适用
Comparison of Tretinoin Cream 0.025% from Cadila Healthcare Limited with RETIN-A (Tretinoin) Cream, 0.025% (Valeant Pharmaceuticals North America LLC., USA) and placebo in the treatment of acne vulgaris
CTRI/2022/04/042178Cadila Healthcare Limited715
已完成
不适用
Comparison of Tretinoin Cream 0.1% from Cadila Healthcare Limited with RETIN-A (Tretinoin) Cream, 0.1% (Valeant Pharmaceuticals North America LLC., USA) and placebo in the treatment of acne vulgaris
CTRI/2022/04/042259Cadila Healthcare Limited570
已完成
3 期
Compare the Efficacy and Safety of Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% Gel in patients with Acne Vulgaris.
CTRI/2018/12/016605Cadila Healthcare Limited650
已完成
不适用
Comparison of Tretinoin Cream 0.025% from Encube Ethicals Pvt. India Ltd with RETIN-A (Tretinoin) Cream, 0.025% (Bausch Health US, LLC Bridgewater, NJ 08807 USA) and placebo in the treatment of acne vulgaris.
CTRI/2022/11/047272Encube Ethicals Private Limited1,060